Intravenous morphine for breakthrough (Episodic-) pain in an acute palliative care unit: A confirmatory study

被引:36
|
作者
Mercadante, Sebastiano [1 ,2 ,3 ]
Intravaia, Giuseppe [1 ,2 ]
Villari, Patrizia [1 ,2 ]
Ferrera, Patrizia [1 ,2 ]
Riina, Salvatore [1 ,2 ]
Mangione, Salvatore [3 ]
机构
[1] Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy
[2] Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy
[3] Univ Palermo, Dept Anesthesiol Intens Care Emergency Med & Pall, Palermo, Italy
关键词
cancer pain; breakthrough-episodic pain; intravenous morphine;
D O I
10.1016/j.jpainsymman.2007.04.018
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by TV-M. Over a one-year period, 99 patients received TV-M for breakthrough pain during 1] 6 admissions. The TV-M dose was 115 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (TO), and to reassess the patient 15 minutes after IV-M injection (T15). Nurses were unaware of the aim of the study and just followed department policy. In total, 945 breakthrough events treated by X-M were recorded and the mean number of events per patient per admission was eight (95% confidence interval (CI) 6.9-9.5). The mean dose of TV-M was 12 mg (95% CI 9-14 mg). In the 469 events (49.6%) with a complete assessment, a decrease in pain of more than 33% and 50% was observed in 28 7 (61.2%) and 115 (24.5%) breakthrough events, respectively. The mean pain intensity decreased from 7.2 (TO) to 2.7 (T15). In eight episodes, no changes in pain intensity were observed and a further dose of IV-M was given. The remaining patients did not require further interventions. No clinical events requiring medical intervention were recorded. In this confirmatory study, IV-M was administered for the management of breakthrough pain in doses proportional to the basal opioid regimen to all patients, including older patients and those requiring relatively large doses. This did not result in life-threatening adverse effects in a large number of patients and was effective in most cases. The role of nurses is of paramount importance in monitoring and collecting data and gathering information for audit purposes on the unit.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 50 条
  • [1] Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine
    Mercadante, Sebastiano
    Villari, Patrizia
    Ferrera, Patrizia
    Porzio, Giampiero
    Aielli, Federica
    Verna, Lucilla
    Casuccio, Alessandra
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 32 (02) : 175 - 179
  • [2] Breakthrough and Episodic Cancer Pain from a Palliative Care Perspective
    Lohre, Erik Torbjorn
    Jakobsen, Gunnhild
    Solheim, Tora Skeidsvoll
    Klepstad, Pal
    Thronaes, Morten
    CURRENT ONCOLOGY, 2023, 30 (12) : 10249 - 10259
  • [3] Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose
    Mercadante, S
    Villari, P
    Ferrera, P
    Bianchi, M
    Casuccio, A
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 27 (04) : 352 - 359
  • [4] The Use of Opioids for Breakthrough Pain in Acute Palliative Care Unit by Using Doses Proportional to Opioid Basal Regimen
    Mercadante, Sebastiano
    Villari, Patrizia
    Ferrera, Patrizia
    Mangione, Salvatore
    Casuccio, Alessandra
    CLINICAL JOURNAL OF PAIN, 2010, 26 (04) : 306 - 309
  • [5] Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
    Mercadante, S.
    Villari, P.
    Ferrera, P.
    Casuccio, A.
    Mangione, S.
    Intravaia, G.
    BRITISH JOURNAL OF CANCER, 2007, 96 (12) : 1828 - 1833
  • [6] Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
    S Mercadante
    P Villari
    P Ferrera
    A Casuccio
    S Mangione
    G Intravaia
    British Journal of Cancer, 2007, 96 : 1828 - 1833
  • [7] Episodic (breakthrough) pain - Consensus conference of an expert working group of the European Association for Palliative Care
    Mercadante, S
    Radbruch, L
    Caraceni, A
    Cherny, N
    Kaasa, S
    Nauck, F
    Ripamonti, C
    De Conno, F
    CANCER, 2002, 94 (03) : 832 - 839
  • [8] Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit
    Mercadante, Sebastiano
    Prestia, Giovanna
    Ranieri, Maurizio
    Giarratano, Antonello
    Casuccio, Alessandra
    SUPPORTIVE CARE IN CANCER, 2013, 21 (07) : 1853 - 1859
  • [9] A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center
    Mercadante, S
    Villari, P
    Ferrera, P
    SUPPORTIVE CARE IN CANCER, 2003, 11 (02) : 114 - 119
  • [10] Intravenous morphine can avoid distressing constipation associated with oral morphine: A retrospective analysis of our experience in 11 patients in the palliative care in-patient unit
    Mazumdar, Ashish
    Mishra, Seema
    Bhatnagar, Sushma
    Gupta, Deepak
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2008, 25 (04) : 282 - 284